Age-related results over 2 years of the multicenter Spanish study of atropine 0.01% in childhood myopia progression.

To evaluate the age-related efficacy and safety of atropine 0.01% eye drops over 2 years for myopia control in a multicentric pediatric Spanish cohort. A non-controlled, interventional, prospective multicenter study was conducted as an extension of the Spanish Group of Atropine Treatment for Myopia Control Study (GTAM 1). Children aged 6-14 years with myopia from - 2.00 to - 6.00 D, astigmatism < 1.50 D and documented annual myopic progression of at least - 0.50 D under cycloplegic examination were recruited. From the original cohort of 105 participants, 92 children who had been receiving atropine 0.01% eye drops once nightly in each eye for 1 year continued their participation in this extended study (GTAM 2). All the patients underwent a standardized quarterly follow-up protocol, which included measurements of best-corrected visual acuity (BCVA), cycloplegic autorefraction, axial length (AL), anterior chamber depth (ACD), and pupil diameter. The study sample was divided into three age groups: 6-8, 9-11, and 12-14 years old. The mean change in cycloplegic spherical equivalent (SE) and axial length (AL) during the 24 months of follow-up was analyzed. Correlations between SE and AL, as well as the distribution of annual progression, were evaluated. Adverse effects were recorded using a specific questionnaire. Finally, 81 children completed the follow-up and were included in the analysis. Over the 2-year period, the mean changes in SE and AL were - 0.88 ± 0.60 D and 0.49 ± 0.25 mm, respectively. Additionally, 51 patients (63%) experienced SE annual progression lower than - 0.50 D. The correlation between the progression of SE and AL during the total period of treatment was mild (r = - 0.36; p < 0.001). There were no differences between the first and the second year of treatment in the progression of SE (- 0.42 ± 0.41 D versus - 0.45 ± 0.39 D; p = 0.69) or AL (0.25 ± 0.16 mm versus 0.23 ± 0.14 mm; p = 0.43). Older patients (12-14 years old) showed less AL progression than younger children (6-8 years old): 0.36 ± 0.18 mm versus 0.59 ± 0.30 mm; p = 0.01. Adverse effects were mild, infrequent, and decreased over time. On average, the myopia progression in control groups from other published biannual studies exceeded that observed in our study. Over 2 years, atropine 0.01% demonstrated a safe treatment for controlling myopia progression in a multicentric cohort of Spanish children. The effect remained stable during this period. Older patients exhibited a more favorable response in terms of AL enlargement. However, further studies are needed to investigate the age-related effect of low-dose atropine in the Caucasian population.

Prediction Error Stabilization and Long-Term Standard Results with a Monofocal Intraocular Lens.

The aim of this study was to assess the stability and differences between objective (O-Rx) and subjective (S-Rx) refraction for the assessment of the prediction error (PE). A secondary aim was to report the results of a monofocal intraocular lens (IOL). 100 subjects were included for whom S-Rx and O-Rx were obtained for all visits, and for visual performance, posterior capsular opacification incidence and Nd:YAG rates at 12 months. Either S-Rx and O-Rx showed a hyperopic shift from 1 to 6 months (p < 0.05) and stabilization after 6 months. S-Rx was related with the axial length (rho = -0.29, p = 0.007), obtaining a major tendency towards hyperopia in short eyes implanted with high-power IOLs. O-Rx showed a myopic shift in comparison to S-Rx (p < 0.05). This resulted in a decrease of the number of eyes in ±0.50 D and ±1.00 D from 79 to 67% and from 94 to 90%, respectively. The median (interquartile range) uncorrected and corrected visual acuities were 0.1 (0.29) and 0 (0.12) logMAR, respectively, and seven eyes required Nd:YAG capsulotomy at 12 months. Some caution should be taken in PE studies in which O-Rx is used or S-Rx is measured in a 1-month follow-up. Constant optimization should be conducted for this IOL after S-Rx stabilization.

A multicenter Spanish study of atropine 0.01% in childhood myopia progression.

To evaluate the efficacy and safety of atropine 0.01% eye drops for myopia control in a multicentric pediatric Spanish cohort. An interventional, prospective, multicenter study was designed. Children aged between 6 and 14 years, with myopia between - 2.00 D to - 6.00 D, astigmatism < 1.50 D and documented previous annual progression greater than - 0.5 D (cycloplegic spherical equivalent, SE) were included. Once nightly atropine 0.01% eye drops in each eye were prescribed to all participants for 12 months. Age, gender, ethnicity and iris color were registered. All patients underwent the same follow-up protocol in every center: baseline visit, telephone consultation 2 weeks later and office controls at 4, 8 and 12 months. At each visit, best-corrected visual acuity, and cycloplegic autorefraction were assessed. Axial length (AL), anterior chamber depth and pupil diameter were measured on an IOL Master (Carl Zeiss Meditec, Inc, Dublin, CA). Adverse effects were registered in a specific questionnaire. Mean changes in cycloplegic SE and AL in the 12 months follow-up were analyzed. SE progression during treatment was compared with the SE progression in the year before enrollment for each patient. Correlation between SE and AL, and annual progression distribution were evaluated. Progression risk factors were analyzed by multivariate logistic regression analyses. Of the 105 recruited children, 92 completed the treatment. Mean SE and AL changes were - 0.44 ± 0.41 D and 0.27 ± 0.20 mm respectively. Mean SE progression was lower than the year before treatment (- 0.44 ± 0.41 D versus - 1.01 ± 0.38 D; p < 0.0001). An inverse correlation between SE progression and AL progression (r: - 0.42; p < 0.0001) was found. Fifty-seven patients (62%) had a SE progression less than - 0.50 D. No risk factors associated with progression could be identified in multivariate analyses. Mean pupil diameter increment at 12-months visit was 0.74 ± 1.76 mm. The adverse effects were mild and infrequent, and decreased over the time. Atropine 0.01% is effective and safe for myopia progression control in a multicentric Spanish children cohort. We believe this efficacy might be extensible to the myopic pediatric population from Western countries with similar social and demographic features. More studies about myopia progression risk factors among atropine treated patients are needed.

Global multi-site, prospective analysis of cataract surgery outcomes following ICHOM standards: the European CAT-Community.

PURPOSE: To evaluate in a large sample of patients from 10 different European centers the results of cataract surgery, characterizing the relationship between patient-reported outcomes (PROMs) and clinician-reported outcome measures (CROMs). METHODS: Prospective non-interventional multicenter observational descriptive study analyzing the clinical outcomes of a total of 3799 cases undergoing cataract surgery (mean age: 72.7 years). In all cases, the cataract surgery standard developed by the International Consortium for Health Outcomes Measurements (ICHOM) was used to register the clinical data. Three-month postoperative visual acuity and refraction data were considered CROMs, whereas Rasch-calibrated item 2 (RCCQ2) and total Catquest-9SF score (CQ) were considered PROMs. RESULTS: Postoperative corrected distance visual acuity (CDVA) was 0.3 logMAR or better in 88.7% (2505/2823) of eyes. Mean differences between preoperative and postoperative RCCQ2 and CQ scores were -3.09 and -2.39, respectively. Visual function improvement with surgery was reported by 91.5% (2163/2364) of patients. Statistically significant, although weak, correlations of postoperative CDVA with postoperative refraction, PROMs, and complications were found (0.133 ≤ r ≤0.289, p < 0.001). A predictive model (R2: 0.254) of postoperative CDVA considering 10 variables was obtained, including preoperative CDVA, different ocular comorbidities, age, gender and intraoperative complications. Likewise, another predictive model (R2: 0.148) of postoperative CQ considering a total of 14 variables was obtained, including additionally preoperative CQ, target refraction and previous surgeries. CONCLUSIONS: Cataract surgery provides an improved functional vision in most of patients although this improvement can be limited by ocular comorbidities and complications. The relationship between PROMs and CROMs is multifactorial and complex.

Objective optical quality analysis using double-pass technique in pterygium surgery.

PURPOSE: To analyze objective optical quality changes after pterygium surgical excision using the Optical Quality Analysis System. METHODS: Forty eyes with primary pterygium suitable for surgical treatment were included. Uncorrected distance visual acuity, corrected distance visual acuity (CDVA), objective scattering index (OSI), and cutoff frequency of the modulation transfer function (MTFcutoff) were recorded preoperatively and at 1 and 6 months postoperatively. Slit-lamp measurement of pterygium size was performed to classify them: small in group 1 and medium size/large in group 2. A paired comparative study of all data that included preoperative with 1-month results (comparison A), preoperative with 6-month results (comparison B), and 1 month with sixth-month results (comparison C) was performed. RESULTS: In global analysis, uncorrected distance visual acuity and OSI showed significant changes in comparison A, all parameters in comparison B, and CDVA, OSI, and MTFcutoff in comparison C. When subdividing into groups, in group 1, there was significant improvement between preoperative uncorrected distance visual acuity value and those at 1 and 6 months. Significant improvement in CDVA, OSI, and MTFcutoff values were observed in comparisons B and C. In group 2, MTFcutoff values significantly improved in comparisons B and C. The comparison of mean values between each group at each evaluation showed a lower value for MTFcutoff at 1 month after surgery. A comparative analysis of the evolution between both groups based on pterygium size did not reveal significant differences. CONCLUSIONS: Pterygium can undermine visual quality, and its excision provides significant improvement even at 6 months after surgery. Optical Quality Analysis System proved useful for postoperative outcomes.

Efficacy and stability of AT TORBI 709 M toric IOL.

PURPOSE: To describe the intraocular rotational stability and refractive results of the toric AT TORBI 709 M (former AT.Comfort 464 TLC) intraocular lens (IOL) (Carl Zeiss Meditec AG, Jena, Germany). METHODS: Forty-eight eyes of 32 consecutive patients with cataract and greater than 1 diopter of corneal astigmatism were included. Implantation of the toric IOL was performed after phacoemulsification. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), residual refractive sphere, residual keratometric and refractive cylinders, and toric IOL axis were measured before and 1, 3, and 6 months after surgery. RESULTS: Mean logMAR UDVA and CDVA improved significantly after surgery (P < .05). UDVA was 20/40 or better in 88.1% of eyes and 20/25 or better in 61.9%. CDVA was 20/40 or better in 100% of eyes and 20/25 or better in 90.2%. Mean refractive cylinder decreased significantly from -2.23 ± 1.72 before to -0.43 ± 0.53 after surgery (P < .05). Vector analysis of attempted versus achieved correction showed 100% of eyes within ± 1.00 D and 95.2% within ± 0.50 D for J and 100% of eyes were within ± 1.00 D and 95.2% within ± 0.50 D for J. Mean toric IOL axis rotation was 4.42 ± 4.31 degrees (range: 0 to 16 degrees) and 86% of the lenses rotated less than 10 degrees. CONCLUSIONS: The AT TORBI 709 M IOL has proved to be a predictable and effective device with good rotational stability for the correction of preexisting astigmatism during cataract surgery.

Rotational stability and visual quality in eyes with Rayner toric intraocular lens implantation.

PURPOSE: To assess astigmatic reduction and rotational stability of Rayner T-flex toric intraocular lenses (IOL) (573T and 623T; Rayner Intraocular Lenses Ltd) in a series of cataract surgery patients with corneal astigmatism >1.50 diopters (D). METHODS: This prospective, observational study included 27 eyes from 22 consecutive patients with pre-operative regular corneal astigmatism ≥1.50 D in which Rayner T-flex toric IOL implantation was performed after phacoemulsification. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), residual refractive sphere, residual keratometric and refractive cylinder, and deviation from attempted toric IOL axis were measured. RESULTS: Mean UDVA 3 months after surgery was 0.1042±0.1290 with 20/40 or better in 96% of eyes and 20/25 or better in 52% of eyes. Mean refractive postoperative sphere was 0.25±0.37 D and mean refractive postoperative cylinder was 0.52±0.63 D. Vector analysis of attempted versus achieved visual correction showed that 100% of eyes were within ±1.00 D and 87% of eyes were within ±0.50 D. Mean change in keratometric astigmatism was 0.54±1.33 for J(0) and -0.24±1.17 for J(45) (P>.05). Twenty-five (92.6%) eyes had IOL rotation <10°. CONCLUSIONS: Rayner T-flex toric IOL implantation is an effective and reliable option to correct preexisting astigmatism in cataract surgery.